Join the webinar: Redefining iPSC Genome Editing for Next-Generation Cell Therapies
Wednesday, November 19 | 5 PM CET | 11 AM EST | 8 AM PST
As cell therapy development accelerates, the field faces a persistent challenge: how to perform complex genome edits with high fidelity and efficiency while ensuring safety, preserving genetic integrity, and meeting evolving regulatory expectations.
Join Dr. Suzanne Snellenberg and Dr. Hind Ghezraoui from Cellistic for a discussion on current strategies to improve genome editing performance in iPSC cell line development. The session will include recent evaluations of advanced systems such as STAR-CRISPR™, covering design principles, comparisons of nuclease architectures, and outcomes related to off-target activity, multiplexing capability, and genomic stability.
Highlights of the webinar
- Assess how nuclease architecture influences editing precision, off-target risk, and manufacturability.
- Review comparative data demonstrating the performance of different CRISPR systems.
- Explore how bioinformatic tools are used to design and evaluate genome edits.
Who should attend
This session is designed for:
- Cell therapy developers seeking safer, faster paths from edit design to manufacturable cell lines.
- Biotech and biopharma companies evaluating iPSC or allogeneic platforms requiring complex genome edits.
- Process development and CMC leaders aiming to integrate high-efficiency, GMP-ready editing workflows.
- Regulatory and quality professionals focused on genetic integrity, off-target assessment, and FDA compliance.